Ret Proto-Oncogene Protein (RET) (His tag)

Produktnummer ABIN7317437

Dieses Recombinant Ret Proto-Oncogene-Protein wird in HEK-293 Cells exprimiert.

Kurzübersicht für Ret Proto-Oncogene Protein (RET) (His tag) (ABIN7317437)

Target: Ret Proto-Oncogene (RET)

Protein-Typ: Recombinant

Spezies: Human

Quelle: HEK-293 Cells

Reinheit: > 92 % as determined by reducing SDS-PAGE.

Produktdetails

Aufreinigungstag / Konjugat: Dieses Ret Proto-Oncogene Protein ist gelabelt mit His tag.

Verwendungszweck: Recombinant Human RET Kinase Protein (His Tag)

Sequenz: Met 1-Arg 635

Produktmerkmale: A DNA sequence encoding the extracellular domain of human RET (P07949-1) (Met 1-Arg 635) was fused with a polyhistidine tag at the N-terminus.

Endotoxin-Niveau: < 1.0 EU per μg as determined by the LAL method.

Anwendungsinformationen

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Lyophilized

Rekonstitution: Please refer to the printed manual for detailed information.

Buffer: Lyophilized from sterile PBS, pH 7.4

Lagerung: 4 °C,-20 °C,-80 °C

Informationen zur Lagerung: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.

Antigendetails

Target: Ret Proto-Oncogene (RET)

Andere Bezeichnung: RET Kinase

Hintergrund:

Background: RET proto-oncogene; also known as RET; is a cell-surface molecule that transduce signals for cell growth and differentiation. It contains 1 cadherin domain and 1 protein kinase domain. RET proto-oncogene belongs to the protein kinase superfamily; tyr protein kinase family. RET proto-oncogene is involved in numerous cellular mechanisms including cell proliferation; neuronal navigation; cell migration; and cell differentiation upon binding with glial cell derived neurotrophic factor family ligands. It phosphorylates PTK2/FAK1 and regulates both cell death/survival balance and positional information. RET is required for the molecular mechanisms orchestration during intestine organogenesis; involved in the development of enteric nervous system and renal organogenesis during embryonic life; promotes the formation of Peyer's patch-like structures; modulates cell adhesion via its cleavage; involved in the development of the neural crest. RET proto-oncogene is active in the absence of ligand; triggering apoptosis. RET acts as a dependence receptor; in the presence of the ligand GDNF in somatotrophs (within pituitary); promotes survival and down regulates growth hormone (GH) production; but triggers apoptosis in absence of GDNF. It also regulates nociceptor survival and size; triggers the differentiation of rapidly adapting (RA) mechanoreceptors; mediated several diseases such as neuroendocrine cancers. Defects in RET may cause colorectal cancer; hirschsprung disease type 1; medullary thyroid carcinoma; multiple neoplasia type 2B; susceptibility to pheochromocytoma; multiple neoplasia type 2A; thyroid papillary carcinoma and congenital central hypoventilation syndrome.Immune Checkpoint   Immunotherapy   Cancer Immunotherapy   Targeted Therapy

Synonym: CDHF12;CDHR16;HSCR1;MEN2A;MEN2B;MTC1;PTC;RET-ELE1;RET51

Molekulargewicht: 69.1 kDa

Pathways: RTK Signalweg, Dopaminergic Neurogenesis, Regulation of Cell Size, Tube Formation